Therapeutic Inhibition of Phospho-Tau in the Primate Prefrontal Cortex

Description:

- Abnormal phosphorylation of tau is a classical hallmark of Alzheimer’s and some other neurodegenerative diseases.
- Fine detail analysis of the cellular location of various signaling components in the primate prefrontal cortex (PFC) identified a mechanism whereby phosphorylated tau accumulates with aging.
- Based on this hypothesis, chronic treatment (daily for 6 months) with low doses of a known, now generic, therapeutic was shown to enhance cognition and reduce the level of phosphorylated tau in the primate PFC (see figure).
- A patent application has been filed on this use of the low dose of this generic compound.

PI: Amy Arnsten

Licensing Contact: Christopher Unsworth
christopher.unsworth@yale.edu